

Published in final edited form as:

*Int J Cancer*. 2007 March 1; 120(5): 1046–1054. doi:10.1002/ijc.22394.

## Expression profiling identifies microRNA signature in pancreatic cancer

Eun Joo Lee<sup>1</sup>, Yuriy Gusev<sup>2</sup>, Jinmai Jiang<sup>1</sup>, Gerard J. Nuovo<sup>3</sup>, Megan R. Lerner<sup>2,4</sup>, Wendy L. Frankel<sup>3</sup>, Daniel L. Morgan<sup>2</sup>, Russell G. Postier<sup>2</sup>, Daniel J. Brackett<sup>2,4</sup>, and Thomas D. Schmittgen<sup>1,\*</sup>

<sup>1</sup>College of Pharmacy, Ohio State University, Columbus, OH

<sup>2</sup>Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK

<sup>3</sup>Department of Pathology, Ohio State University Medical Center, Columbus, OH

<sup>4</sup>Veterans Affairs Medical Center, Oklahoma City, OK

### Abstract

microRNAs are functional, 22 nt, noncoding RNAs that negatively regulate gene expression. Disturbance of microRNA expression may play a role in the initiation and progression of certain diseases. A microRNA expression signature has been identified that is associated with pancreatic cancer. This has been accomplished with the application of real-time PCR profiling of over 200 microRNA precursors on specimens of human pancreatic adenocarcinoma, paired benign tissue, normal pancreas, chronic pancreatitis and nine pancreatic cancer cell lines. Hierarchical clustering was able to distinguish tumor from normal pancreas, pancreatitis and cell lines. The PAM algorithm correctly classified 28 of 28 tumors, 6 of 6 normal pancreas and 11 of 15 adjacent benign tissues. One hundred micro-RNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia ( $p < 0.01$ ), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301). Most of the top aberrantly expressed miRNAs displayed increased expression in the tumor. Expression of the active, mature microRNA was validated using a real-time PCR assay to quantify the mature microRNA and Northern blotting. Reverse transcription *in situ* PCR showed that three of the top differentially expressed miRNAs (miR-221, -376a and -301) were localized to tumor cells and not to stroma or normal acini or ducts. Aberrant microRNA expression may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma.

### Keywords

cancer; noncoding RNA; gene expression; real-time PCR

---

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States.<sup>1</sup> The annual death rate over the last five years has been ~30,000 with a similar number of new cases diagnosed each year. The prognosis for pancreatic cancer is the worst of all cancers with a mortality/incidence ratio of 0.99.<sup>2</sup> The incidence of pancreatic cancer in the United States is

---

\*Correspondence to: College of Pharmacy, Ohio State University, Columbus, OH 43210. Fax: 1614-292-7766. E-mail: E-mail: Schmittgen.2@osu.edu.

This article contains supplementary material available via the Internet at <http://www.interscience.wiley.com/jpages/0020-7136/suppmat/>

~9 per 100,000.<sup>3</sup> These discouraging numbers, reflecting the increasing rates of incidence and death, are due to the lack of improvement in detection and diagnosis strategies and the paucity of breakthroughs in treatment regimens.

miRNAs were first discovered in *c. elegans* in 1993<sup>4</sup> and have subsequently been discovered in all multicellular organisms.<sup>5–7</sup> miRNAs are negative regulators of gene expression and are believed to function primarily through imperfect base pair interactions to sequences within the 3' untranslated region of protein coding mRNAs. Presently 326 miRNAs have been discovered in humans.<sup>8</sup> While the role for each of these miRNAs is unknown, specific miRNAs have been implicated in the regulation of a diverse number of cellular processes, including differentiation of adipocytes,<sup>9</sup> maturation of oocytes,<sup>10</sup> maintenance of the pluripotent cell state<sup>11</sup> and regulation of insulin secretion.<sup>12</sup>

A growing number of direct and indirect evidence suggests a relationship between altered miRNA expression and cancer. These include miR-15a and miR-16-1 in chronic lymphocytic leukemia,<sup>13,14</sup> miR-143 and miR-145 in colorectal cancer,<sup>15</sup> let-7 in lung cancer<sup>16,17</sup> and miR-155 in diffuse large B cell lymphoma.<sup>18</sup> Expression profiling has identified other cancers with differential expression of several miRNAs, including breast cancer,<sup>19</sup> glioblastoma<sup>20, 21</sup> and papillary thyroid cancer.<sup>22</sup> A polycistron encoding five miRNAs is amplified in human B-cell lymphomas and forced expression of the polycistron along with c-myc was tumorigenic, suggesting that this group of miRNAs may function as oncogenes.<sup>23,24</sup>

The purpose of this study was to profile the miRNA expression in clinical specimens of pancreatic adenocarcinoma. A real-time, quantitative PCR assay<sup>25,26</sup> was used to profile the expression of over 200 miRNA precursors in clinical specimens of pancreatic cancer and pancreatic cancer cell lines. A unique miRNA signature was identified that distinguished pancreatic cancer from normal and benign pancreas.

## Material and methods

### Tissue procurement

The tissue samples analyzed in this study were derived from patients undergoing a surgical procedure to remove a portion of the pancreas at the University of Oklahoma Health Sciences Center and The Ohio State University. The collection of samples conformed to the policies and practices of the facility's Institutional Review Board. Upon removal of the surgical specimen, research personnel immediately transported the tissue to the surgical pathology lab. Pathology faculty performed a gross analysis of the specimen and selected cancerous appearing pancreatic tissue and normal appearing pancreatic tissue for research. Each sample was placed in a cryovial and flash-frozen in liquid nitrogen and stored at  $-150^{\circ}\text{C}$  until analysis. Subsequent pathologic analysis by the institutes providing the surgical specimens confirmed the histopathology of the samples taken for research. A second level of quality control was performed on the adjacent benign tissues by the laboratory who performed the RNA analysis. Histological slides were prepared from the section of the frozen tissue directly adjacent to tissue from which RNA was isolated. These slides were examined by one of us (W.L.F.) to determine if the benign tissues contained any pancreatic tumor cells. Benign tissue that contained residual tumor was not included in the study. The clinical data on the specimens are listed in Table I.

### Cell lines

The following pancreatic tumor cell lines were purchased from American Type Tissue Collection (Manassas, VA). Panc-1, HS766T, MIA PaCa-2, HPAF-II, BxPC-3, Mpanc-96, PL45, Panc03.27 and Panc10.05. Cell lines were cultured in RPMI 1640 medium with 10% FBS or other optimized complete medium using standard conditions.

### miRNA precursor expression profiling

Total RNA was isolated from the cell lines or tissues in 1 ml of Trizol (Invitrogen, Carlsbad, CA). Frozen tissue (~10 mg) were first pulverized in a stainless steel mortar and pestle. Total RNA from normal pancreases were purchased from Ambion (Austin, TX), BD Biosciences (Mountain View, CA) and Stratagene (La Jolla, CA). All donors of the normal tissue died from complications other than pancreatic diseases (Table I). RNA concentration was determined by analyzing 1  $\mu$ l of solution using the ND-1000 micro-spectrophotometer (NanoDrop Technologies, Wilmington, DE). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA integrity number (RIN) was determined using the RIN algorithm of the Agilent 2100 expert software<sup>27</sup> (Table I). RNA with a RIN  $\geq 4$  was included in the study. RNA was briefly treated with RNase-free DNAase I and cDNA was synthesized from 1  $\mu$ g of total RNA using gene specific primers to 222 miRNA precursors plus 18S rRNA as described.<sup>25,26</sup> The expression of 222 miRNA precursors was profiled using a real-time quantitative PCR assay.<sup>25,26</sup> Duplicate PCRs were performed for each miRNA precursor gene in each sample of cDNA. The mean  $C_T$  was determined from the duplicate PCRs. Relative gene expression was calculated as  $2^{-(C_{TmiRNA}-C_{T18S\ rRNA})}$ . Relative gene expression was multiplied by  $10^6$  to simplify the presentation of the data. The raw relative miRNA precursor expression data are provided in Supplemental Table 1.

### Real-time PCR of mature miRNA

Assays to quantify the mature miRNA (i.e. TaqMan® microRNA Assays, Applied Biosystems Foster City, CA) were conducted as described<sup>28</sup> with one modification. A 5 $\times$  cocktail containing 28 different antisense looped RT primers was prepared by concentrating the 2 $\times$  stock solutions in a Speed Vac. One hundred nanograms of total RNA was heated for 5 min at 80°C and then incubated for 5 min at 60°C with 10  $\mu$ M of the 18S rRNA antisense primer followed by cooling to room temperature. Three microliters of the 5 $\times$  looped primer mix was then added and the cDNA was made as described.<sup>28</sup> This allowed for the creation of a library of 28 miRNA cDNAs plus the 18S rRNA internal control. Real-time PCR (10  $\mu$ l total reaction) was performed as described<sup>28</sup> using 1  $\mu$ l of a 1:50 dilution of cDNA. Duplicate PCRs were performed for each mature miRNA gene in each sample of cDNA. The mean  $C_T$  was determined from the duplicate PCRs. Gene expression was calculated relative to 18S rRNA as described earlier and multiplied by  $10^6$  to simplify data presentation.

### Northern blotting

Northern blotting was performed as previously described.<sup>6,26</sup> DNA oligonucleotides of the reverse complement to the mature miRNA were used as probes. Blots were successfully stripped and reprobed up to 3 times.

### RT in situ PCR

The RT *in situ* PCR protocol was performed as previously described.<sup>29</sup> Briefly, optimal protease digestion time was determined using nonspecific incorporation of the reporter nucleotide digoxigenin dUTP. Optimal protease digestion was followed by overnight incubation in RNase-free DNase (10 U per sample, Boehringer Mannheim, Indianapolis, IN) and one step RT/PCR using the *rT*<sup>th</sup> system and digoxigenin dUTP. The chromogen is nitro-blue tetrazolium and bromochloroindolyl phosphate (NBT/BCIP) with nuclear fast red as the counterstain. The primer sequences to the precursors of miR-221, miR-301 and miR-376a were the same as those used for the profiling.<sup>25</sup> The negative controls included omission of the primers and substitution with irrelevant (human papillomavirus specific) primers, as this virus does not infect pancreatic tissue. RT *in situ* PCR was performed on the archived, formalin-fixed paraffin-embedded sample 1050005A2(T) (Table I).

## Statistics

The  $\Delta C_T$  data for 201 gene expression values (relative to control gene expression) were mean-centered and analyzed using the following strategy. The expression patterns of unfiltered data were assessed using unsupervised hierarchical clustering of samples and unsupervised hierarchical clustering of genes based on average linkage and Euclidian distance.<sup>30,31</sup> To determine genes that are differentially expressed between groups of samples, the data were filtered on significance of differences using multi-group permutations-based ANOVA test (Welch approximation) with  $p < 0.01$  (10,000 random permutations) and multiple testing correction (Westfall-Young step-down correction with maxT). To compare the expression patterns of differentially expressed genes, the filtered data were analyzed using hierarchical clustering of samples and hierarchical clustering of genes based on average linkage and Euclidian distance.<sup>30,31</sup>

Additional cluster analysis of filtered data was done using an expression terrain map.<sup>32</sup> Terrain maps provide a three-dimensional overview of the major clusters inherent in the data. Samples were first mapped into a two-dimensional grid in which the placement of each element is influenced by a number of nearest neighbors based on Euclidian distance that was calculated using miRNA precursor expression data. The third dimension is determined by the density of points over the two-dimensional grid and its' value is projected as a surface; higher peaks indicate larger numbers of very similar elements. The average correlation between each pair of samples was also calculated. Each pair of samples with an average correlation above the threshold (0.8) is indicated on the expression terrain map by a line connecting the two samples. This allows visualizing subsets of samples with a highly correlated pattern of miRNA expression. Peaks representing samples from a particular cluster are labeled with color coded spheres on top of each peak.

A supervised machine learning algorithm was applied for classification of samples based on unfiltered miRNA expression data. The predictive scores for each miRNA were calculated based on 2 class comparison (normal vs. tumor) of expression data using the prediction analysis of micro-arrays algorithm (PAM)<sup>33</sup> based on training, take-one-out cross validation and testing procedures. The division of the samples into training and test sets is done using the commonly accepted approach of randomly splitting data into training and test sets (usually 2/3 for train, 1/3 for test).<sup>33</sup> For this study, tumor samples were randomly split into ~75% for training and 25% for testing. Since the number of normal cases was small ( $N = 6$ ), normal cases were included in the training set only. The small number of chronic pancreatitis samples ( $N = 4$ ) were not included in the PAM analysis. While, two levels of quality control were performed to eliminate adjacent benign tissue that contained any tumor cells, the RNA was extracted from whole tissue rather than microdissected tissue. Thus, we could not completely rule out the possibility that some tumor cells contaminated the adjacent benign, nor do we know if early premalignant changes have occurred in these benign samples that are obtained from tissue adjacent to tumor. Therefore benign samples were excluded from the training set in order to train the classifier on true normal and tumor cases. Benign cases were used in the test set.

## Results

### Validation

Pancreatic tissue is rich in ribonuclease and care must be taken during RNA isolation to reduce the possibility of autolysis. To validate the integrity of the RNA isolated from the pancreatic tissue, ~100 ng of each RNA sample was assayed using the Agilent 2100 Bioanalyzer. Fifty-two tissues had a RIN  $\geq 4$  (median 7.6, range 4.3–9.6, Table I).

miRNA precursor expression in each of the samples was determined using real-time PCR and normalized to an internal control gene. Since equivalent amounts of total RNA was added to each RT reaction, 18S rRNA was validated as the internal control by comparing the mean expression among the various samples (i.e. tumor, normal and benign). There was no statistically significant difference in the mean 18S rRNA expression between the tumor samples or the normal pancreas ( $p = 0.116$ , Fig. 1). The 18S rRNA expression in the tumor and normal tissue determined here are in agreement with those previously reported in pancreatic tissue.<sup>34</sup> Since there was no significant difference in the 18S rRNA expression between the tumor, normal and benign groups, 18S rRNA was selected as the internal control gene in the study.

### miRNA precursor profiling in pancreatic tissues

The expression of 201 miRNA precursors, representing the 222 miRNAs discovered as of April, 2005 was profiled in 28 tumors, 15 adjacent benign tissues, 4 chronic pancreatitis specimens, 6 normal pancreas tissues and 9 pancreatic cancer cell lines. Unsupervised hierarchical clustering of samples was performed on the entire set of unfiltered data. The heatmap demonstrates that unfiltered expression data of only 201 miRNA precursors sufficiently sorts the samples into clusters of normal pancreas, tumor and cell lines (Supplemental Fig. 1). While most of the benign samples clustered together with the normal pancreas samples, several benign samples clustered with the tumor samples or pancreatitis.

The miRNA precursor expression data was filtered using multigroup ANOVA. Statistical filtering of data is conventionally considered to be a required step of the expression data preprocessing because gene expression data are inherently noisy. Hierarchical clustering of samples and genes was performed on the resulting 112 miRNAs. Hierarchical clustering of filtered data allowed us to identify major groups of miRNAs that have different patterns of expression in the resulting four clusters of samples (Fig. 2a,b). One cluster contained only cell lines. Another cluster contained all 6 normal pancreases and 9 of 15 benign tissues. A third cluster contained the 4 chronic pancreatitis specimens and 1 benign tissue. Finally, a large cluster contained 28 of 28 tumors and 5 benign tissues (Fig. 2a,b).

The filtered data were also analyzed using a different clustering technique known as expression terrain maps.<sup>32</sup> The terrain map separated the expression data into 5 main groups of samples (Fig. 2c). Like the hierarchical clustering, the terrain map separates groups of samples from the normal pancreas, the cell lines, pancreatic adenocarcinomas and chronic pancreatitis. This analysis showed that each of the clusters of samples occupies distinct regions on the expression terrain map thus providing additional evidence that each of the 4 groups of samples has distinct patterns of miRNA expression and suggests the possibility of finding subsets of microRNAs that discriminate normal and tumor samples. Most of the adjacent benign tissue grouped in between the normal and tumor, while those benign samples that clustered with the tumor also grouped with the tumor on the terrain map (Fig. 2). As an additional feature of terrain map, the average correlations of all miRNA expression values were calculated between each pair of samples. Those correlations above the threshold of 0.8 are shown as lines connecting pairs of samples with similar patterns of miRNA expression. This allows visualizing subsets of samples with a highly correlated pattern of miRNA expression. The samples within each of the 4 main groups are connected (i.e. average correlation  $>0.8$ ) but there were no between the groups connections, except for two pancreatitis samples that correlated with some of the tumor samples (Fig. 2c).

Comparing the gene expression profile among different pancreas tissues has been used to eliminate the stroma and cell proliferation (e.g. cell line) contributions and identify genes expressed in pancreatic tumors.<sup>35–37</sup> An attempt to perform such analysis on the miRNA expression data in Figure 2a was unsuccessful due to the uniformly high expression in the



cancer cell lines and the uniformly low expression in the pancreatitis samples. However, a number of possible tumor-related miRNAs were identified that were increased in the cell lines or tumors but not in the normal or pancreatitis (Fig. 2a).

### Data analysis by prediction analysis of micro-arrays algorithm (PAM)

The PAM classification algorithm was used to determine if the miRNA expression data could predict which class the samples fit (tumor or normal) and to determine the most important, differentially expressed miRNAs related to pancreatic adenocarcinoma. The unfiltered data on 201 pre-miRNAs were analyzed by the PAM algorithm.<sup>33</sup> The 3 genes with more than 75% of missing data were eliminated from the analysis in order to prevent possible artifacts of the imputation algorithm. PAM training and cross-validation were conducted using the 6 normal pancreas and 18 pancreatic tumors. PAM has correctly classified 100% of the normal and tumor samples (Fig. 3a). PAM testing was conducted on 10 tumor samples and 15 adjacent benign samples. PAM has correctly classified 100% of the tested tumor samples and 11 of 15 of the tested benign samples (Fig. 3b). The 20 top ranked differentially expressed miRNAs in pancreatic adenocarcinoma as selected by PAM are listed in Table II.

### Validation of miRNA expression

The real-time PCR assay used in this study quantifies the miRNA precursors and not the active, mature miRNA.<sup>25,26</sup> Northern blotting was performed on the identical RNA used in the real-time PCR analysis to validate if the mature miRNA correlated with the precursor. Expression levels of mature miR-100, miR-375 and miR-155 from 4 normal pancreases and 5 pairs of tumor/adjacent benign tissue paralleled the miRNA precursor levels by PCR (Fig. 4). miR-100 and miR-155 were among the top 20 differentially expressed miRNAs (Table II). miR-375 was validated by Northern blotting because it was one of the few miRNAs with decreased expression in pancreas cancer. While miR-375 was not among the top 20 miRNAs (Table II), the expression of both precursor and mature miR-375 was significantly decreased in pancreas cancer by real-time PCR ( $p < 1 \times 10^{-5}$ ). miRNA expression in the paired benign and tumor tissue was consistently increased or decreased in all cases, demonstrating that the differences in miRNA expression between tumor and benign are due to differences in individual patient's tissues and not due to differences in the mean expression of the group.

The real-time PCR data was further validated using a commercially available real-time PCR assay to amplify and quantify the mature miRNA. Mature miRNA expression was validated on 8 of the top aberrantly expressed miRNAs from PAM. cDNA from the following tissues were assayed: 6 normal pancreases, 16 pancreatic adenocarcinomas and 10 adjacent benign tissues that were predicted as normal from PAM. The mature miRNA expression highly correlated with the miRNA precursor (Fig. 5). To our knowledge, this is the initial presentation of both precursor and mature miRNA expression determined by sensitive, real-time PCR assays. A direct comparison between the precursor and mature PCR data presented in Fig. 5 is not possible. Among other reasons, different amounts of RNA were added to each RT, 1  $\mu$ g for the precursor assay and 100 ng for the mature. Despite these differences, the relative amount of mature miRNA is greater than the precursors in all cases except for panel H. This demonstrates that the steady state levels of mature miRNA are more predominant than the precursors, a fact that is documented on nearly all published Northern blots that show the band intensity of the mature is more intense than the precursor. We have no explanation as to why this situation is apparently reversed in the case of panel H (miR-212). Of interest is that while the relative expression values for these mature miRNAs spanned 3-logs (from 0.1 to 100), the trend in differential expression between the tumor and normal tissues remained (Fig. 5). This suggests that miRNAs function in tumor and normal pancreas at different expression levels, yet the differential expression is maintained between cancer and normal tissue.

Finally, the cell-type miRNA expression was studied using RT *in situ* PCR. miR-221, miR-376a and miR-301 were selected for the *in situ* PCR since they were among the top differentially expressed miRNAs (Table II) and had increased expression in the tumor and cell lines compared to the normal pancreas and pancreatitis (Fig. 2). We were particularly interested in the cell type expression of miR-376a since it was cloned from pancreas cells.<sup>12</sup> miR-221 and miR-376a are localized to the tumor cells and not to the benign pancreatic acini or stromal cells (Fig. 6) or benign ducts (not shown). miR-301 was also localized to tumor (data not shown).

## Discussion

Reported here are the results of the first detailed miRNA expression profiling study in pancreatic ductal adenocarcinoma. Expression profiling identified a large number of miRNAs that are aberrantly expressed in pancreatic ductal adenocarcinoma. A bead-based flow cytometric assay was used previously to profile the expression of 217 miRNAs in nine samples of pancreatic adenocarcinoma.<sup>38</sup> A micro chip assay was recently used to profile the expression of miRNAs in 39 samples of endocrine pancreas cancer.<sup>39</sup> Our results in pancreatic ductal adenocarcinoma more closely approximate those of Volinia, et al.,<sup>39</sup> in endocrine pancreas tumors and show that the majority of miRNAs are increased in the tumor compared to normal pancreas. Many of the miRNAs that are increased in both pancreas adenocarcinoma and endocrine pancreas cancer are similar, including miR-221, -100, -125b and -21. On the other hand, Lu, et al.,<sup>38</sup> report an almost universal decrease in miRNA expression in the pancreatic adenocarcinomas compared to normal pancreas.

miRNAs are believed to function primarily as negative regulators of gene expression following binding to conserved sequences within the 3' untranslated region of target mRNAs. While the biological roles of miRNA are under intense investigation, they are believed to define and maintain cellular fate in a manner similar to transcription factors<sup>40</sup> by regulating developmental timing and differentiation.<sup>41</sup> Since alterations in developmental pathways play a critical role in pancreatic cancer development,<sup>42,43</sup> alterations in miRNA expression may be an important contributor to the development of pancreatic adenocarcinoma.

Our study is unique in that a sensitive, real-time PCR assay was used to profile a relatively small number of noncoding RNAs. Real-time PCR is the gold standard of RNA quantification and has much less technical noise and greater reproducibility than traditional cDNA microarrays. miRNA expression profiling correctly identified 28 of 28 tissues as tumor (Fig. 3). All 6 normal pancreases were correctly predicted and 11 of 15 adjacent benign tissues were classified as normal tissue (Fig. 3). The data presented here reinforces the argument that miRNA expression profiling may generate a unique molecular signature for a given cancer. This concept is supported by several recent studies. Profiling of various cancers revealed that the pattern of miRNA expression varies markedly across different tumors and that a small number of miRNAs define the cancer better than expression data from 16,000 mRNAs.<sup>38</sup> A unique expression signature of only 13 miRNAs differentiated cases of the more aggressive form of chronic lymphocytic leukemia from the more indolent form and was associated with the presence or absence of disease progression.<sup>44</sup>

The 3 factors that are likely driving the differences in gene expression are the normal acini, stroma and tumor cells. We cannot conclude that each of the aberrantly expressed miRNAs (Table II) reflect a difference in expression between normal ductal epithelium and tumor and may reflect differences in expression among the different cell types (stoma, acini and tumor). However, we confirmed by RT *in situ* PCR that 3 of the top differentially expressed miRNAs that were identified in the screen are localized to the tumor cells (Fig. 6). We cannot explain why some of the benign tissues failed to cluster with the normal pancreas (Fig. 2).

While 2 levels of quality control were used to reduce the possibility of contaminating tumor cells, it is possible that some tumor cells were present in the benign tissue since the RNA was isolated from whole tissue and not microdissected tissue. Another possibility is that premalignant changes have already occurred in some of the benign tissues as those samples are obtained from tissue adjacent to tumor. It is interesting that most of the benign samples (and chronic pancreatitis as well) lie in between the normal pancreas and tumor on the expression terrain map (Fig. 2c). This observation may indeed describe the premalignant alterations that have occurred in these benign tissues. Future studies using RT *in situ* PCR and perhaps laser microdissection will be able to address these issues in more detail.

Some of the differentially expressed miRNAs in pancreatic cancer were aberrantly expressed in other cancers. These include miR-155, which was increased in the present study and in diffuse large B-cell lymphoma<sup>18</sup>; miR-21 was increased here and in glioblastomas,<sup>20,21</sup> breast cancer<sup>19</sup> and papillary thyroid cancer<sup>22</sup>; miR-221 was increased in pancreatic cancer, in glioblastoma<sup>21</sup> and in thyroid cancer.<sup>22</sup> miR-221 is located ~700 bp from miR-222 on the X chromosome; both miR-221 and miR-222 are predicted to bind to and regulate kit.<sup>22,45</sup> miR-222 precursor was not among the top 20 differentially expressed miRNAs (Table II); however, subsequent analysis of mature miR-222 by PCR showed that miR-222 was increased in pancreas cancer at levels that were similar to miR-221 (data not shown). Thus, deregulation of the miRNAs mentioned earlier may be unique to cancer in general. miRNAs differentially expressed in other cancers were not deregulated to the same degree in pancreatic cancer. The let-7 family, decreased in lung cancer,<sup>16,17</sup> was increased here. Expression of the miR-17-92 polycistron (encoding miR-17, -18, -19a, -19b-1 and -92-1) was increased in lymphoma and colorectal cancer<sup>24</sup> but was not significantly altered in pancreatic cancer. We report deregulation of a number of miRNAs in pancreatic cancer such as miR-376a and miR-301 that have not been reported in any other cancers to our knowledge. Also of interest is the fact that most of the deregulated miRNAs reported here show increased expression in the tumors compared to the normal pancreas. A few miRNAs had reduced expression in pancreatic cancer including miR-375 (Fig. 4). miR-375 was cloned from pancreas and is believed to be islet cell specific.<sup>12</sup>

We report significant changes in miRNA expression between pancreatic adenocarcinoma and normal pancreas. Since each miRNA may regulate scores of mRNAs,<sup>46</sup> the impact on gene expression in pancreatic cancer may be profound. The miRNA field is currently hampered by a lack of methods to sort through the many hundreds of predicted miRNA target genes. As more sophisticated approaches become available to identify and validate miRNA targets, the role of aberrant miRNA expression in pancreas cancer will become better understood.

## Acknowledgements

Supported by an NIH grant CA107435 to T.D.S. The Tissue Procurement Shared Resource at The Ohio State University funded by the National Cancer Institute, grant P30 CA16058. We thank Dr. Caifu Chen at Applied Biosystems for his assistance with the TaqMan looped primer assays.

## References


1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. *CA Cancer J Clin* 2005;55:10–30. [PubMed: 15661684]
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. *Cancer* 1995;76:1671–1677. [PubMed: 8635074]
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. *N Engl J Med* 1992;326:455–465. [PubMed: 1732772]
4. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* 1993;75:843–854. [PubMed: 8252621]




5. Lee RC, Ambros V. An extensive class of small RNAs in *Caenorhabditis elegans*. *Science* 2001;294:862–864. [PubMed: 11679672]
6. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* 2001;294:858–862. [PubMed: 11679671]
7. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. *Science* 2001;294:853–858. [PubMed: 11679670]
8. Griffiths-Jones S. The microRNA Registry. *Nucleic Acids Res* 2004;32:D109–D111. [PubMed: 14681370]
9. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, Dean NM, Freier SM, et al. Micro-RNA-143 regulates adipocyte differentiation. *J Biol Chem* 2004;279:52361–52365. [PubMed: 15504739]
10. Nakahara K, Kim K, Sciulli C, Dowd SR, Minden JS, Carthew RW. Targets of microRNA regulation in the *Drosophila* oocyte proteome. *Proc Natl Acad Sci USA* 2005;102:12023–12028. [PubMed: 16099838]
11. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific microRNAs. *Dev Cell* 2003;5:351–358. [PubMed: 12919684]
12. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M. A pancreatic islet-specific microRNA regulates insulin secretion. *Nature* 2004;432:226–230. [PubMed: 15538371]
13. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 2004;101:11755–11760. [PubMed: 15284443]
14. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci USA* 2004;101:2999–3004. [PubMed: 14973191]
15. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol Cancer Res* 2003;1:882–891. [PubMed: 14573789]
16. Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert K, Brown D, Slack F. RAS is regulated by the let-7 microRNA family. *Cell* 2005;120:635–647. [PubMed: 15766527]
17. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res* 2004;64:3753–3756. [PubMed: 15172979]
18. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. *Proc Natl Acad Sci USA* 2005;102:3627–3632. [PubMed: 15738415]
19. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, et al. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res* 2005;65:7065–7070. [PubMed: 16103053]
20. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. *Cancer Res* 2005;65:6029–6033. [PubMed: 16024602]
21. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. *Biochem Biophys Res Commun* 2005;334:1351–1358. [PubMed: 16039986]
22. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, et al. The role of microRNA genes in papillary thyroid carcinoma. *Proc Natl Acad Sci USA* 2005;102:19075–19080. [PubMed: 16365291]
23. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* 2005;435:839–843. [PubMed: 15944709]

24. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. *Nature* 2005;435:828–833. [PubMed: 15944707]
25. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. *Nucleic Acids Res* 2005;33:5394–5403. [PubMed: 16192569]
26. Schmittgen TD, Jiang J, Liu Q, Yang L. A high-throughput method to monitor the expression of microRNA precursors. *Nucleic Acids Res* 2004;32:E43. [PubMed: 14985473]
27. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, Eveno E, Mueller O, Schroeder A, Auffray C. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. *Nucleic Acids Res* 2005;33:e56. [PubMed: 15800207]
28. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res* 2005;33:e179. [PubMed: 16314309]
29. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. *Proc Natl Acad Sci USA* 1999;96:12754–12759. [PubMed: 10535995]
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* 1998;95:14863–14868. [PubMed: 9843981]
31. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, et al. TM4: a free, open-source system for microarray data management and analysis. *Biotechniques* 2003;34:374–378. [PubMed: 12613259]
32. Kim SK, Lund J, Kiraly M, Duke K, Jiang M, Stuart JM, Eizinger A, Wylie BN, Davidson GS. A gene expression map for *Caenorhabditis elegans*. *Science* 2001;293:2087–2092. [PubMed: 11557892]
33. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. *Proc Natl Acad Sci USA* 2002;99:6567–6572. [PubMed: 12011421]
34. Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, Brittner B, Ludwig B, Schilling M. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. *Mol Cell Probes* 2005;19:101–109. [PubMed: 15680211]
35. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. *Am J Pathol* 2003;162:1151–1162. [PubMed: 12651607]
36. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. *Cancer Res* 2003;63:2649–2657. [PubMed: 12750293]
37. Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuick R, Misek D, Hanash S, Logsdon CD, Simeone DM. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. *Pancreas* 2004;29:254–263. [PubMed: 15502640]
38. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, et al. MicroRNA expression profiles classify human cancers. *Nature* 2005;435:834–838. [PubMed: 15944708]
39. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006;103:2257–2261. [PubMed: 16461460]
40. Hobert O. Common logic of transcription factor and microRNA action. *Trends Biochem Sci* 2004;29:462–468. [PubMed: 15337119]
41. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. *Development* 2005;132:4653–4662. [PubMed: 16224045]
42. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 2003;425:851–856. [PubMed: 14520413]

43. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, et al. Notch mediates TGF  $\alpha$ -induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell* 2003;3:565–576. [PubMed: 12842085]
44. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 2005;353:1793–1801. [PubMed: 16251535]
45. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, et al. Micro-RNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. *Proc Natl Acad Sci USA* 2005;102:18081–18086. [PubMed: 16330772]
46. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15–20. [PubMed: 15652477]




**FIGURE 1.** 18S rRNA expression in pancreatic tissue. The expression of the 18S rRNA internal control is shown in pancreatic tumors, adjacent benign tissue, normal pancreas, chronic pancreatitis and pancreatic cancer cell lines. 18S rRNA expression, determined using real-time PCR as described in Material and Methods, is presented as 2<sup>-CT</sup>. Dashed line, mean value.




**FIGURE 2.** miRNA precursor expression in pancreatic samples. (a) The relative expression of each miRNA precursor was determined by real-time PCR; data are presented as  $\Delta C_T$ . Hierarchical clustering was performed on a subset of 112 genes that are differentially expressed ( $p < 0.001$ ) among groups (tumor, chronic pancreatitis, cell lines and normal tissue) as determined by ANOVA multi-group comparison test. A median expression value equal to 1 was designated black; red, increased expression; green, reduced expression; grey, undetectable expression. (b) Dendrogram representing the results of hierarchical clustering analysis of the miRNA precursor expression pattern in 62 samples. Samples include primary pancreatic tumors ( $N = 28$ ), normal pancreatic tissues ( $N = 6$ ), adjacent benign pancreas ( $N = 15$ ), chronic pancreatitis




( $N = 4$ ) and pancreatic cancer cell lines ( $N = 9$ ). (c) Three-dimensional expression terrain map was created from the filtered miRNA precursor expression data presented in (a). Each mountain represents an individual sample (tumor, adjacent benign, chronic pancreatitis, normal pancreas or pancreatic cancer cell line). The individual mountains sort into small groups based upon their similarities or differences to each other. Colored dots represent the same clusters as in (b). Black dots represent the 6 normal pancreases. The lines connecting pairs of samples indicate those samples which have very similar patterns of miRNA expression with average correlation above the threshold ( $>0.8$ ).



**FIGURE 3.** Estimated probabilities for the training and test data. All training data including 6 normal pancreas samples and 18 of the samples known to be pancreatic tumors are correctly classified (a). Eleven out of 15 adjacent benign samples and 10 samples known to be pancreatic tumors are correctly classified in the testing group (b). Samples are partitioned by the true class (a) and the predicted class (b).




**FIGURE 4.** miRNA expression by Northern blotting. The expression of miR-100, miR-375 and miR-155 was determined in tissue specimens of pancreatic cancer (T), adjacent benign tissue (B) or normal pancreas (N). Blots were stripped and reprobbed. tRNA, visualized by ethidium bromide staining, was used as a loading control.



**FIGURE 5.**

Validation of precursor and mature miRNA levels. The expression of 8 miRNAs was validated in 6 normal pancreas specimens, 10 adjacent benign tissues and 16 pancreatic adenocarcinomas. The relative expression of the miRNA precursors (open bars) was determined using a real-time PCR assay to the miRNA precursors while the relative expression of the mature miRNA (closed bars) was determined using a real-time PCR assay to the mature miRNAs. The mean differences in miRNA expression between the normal pancreas (black) and tumors (red) was significant  $p < 0.01$  (student's  $t$ -test). (a) let-7i, (b) miR-221, (c) miR-100, (d) miR-301, (e) miR-21, (f) miR-181a,c (precursor) and miR-181a (mature), (g) miR-125b-1 (precursor) and miR-125b (mature), (h) miR-212.





**FIGURE 6.**

Histologic and molecular analyses of pancreatic cancer for microRNA expression. Panel (a) ( $\times 400$ ) depicts the hematoxylin and eosin analysis of a pancreatic adenocarcinoma. The normal pancreatic glands (small arrow) are being invaded by the poorly formed glands of the carcinoma (large arrow). Serial section analysis of miR-221 after *in situ* amplification of the corresponding cDNA showed that many of the tumor cells contained the target sequence; note the cytoplasmic localization (arrows, panel (b) –  $\times 400$  and at higher magnification, panel (c) –  $\times 1,000$ ; the signal is blue due to NBT/BCIP with negative cells counterstained with fast red). The signal was lost with either omission of the primers or substitution with HPV-specific primers (panel (d),  $\times 400$ ). The adjacent serial section also showed many of the tumor cells expressed miR-376a



after *in situ* amplification of the cDNA (*e, f*). Panel (*e*) ( $\times 400$ ) shows the positive tumor cells (large arrow) and the negative stromal cells in the areas of desmoplasia (small arrow) while panel (*f*) ( $\times 400$ ) depicts the positive tumor cells (large arrow) adjacent to the negative benign pancreatic gland acini (small arrow).

TABLE I

Clinical data and tumor pathology

<i>Normal pancreas tissues</i>					
Sample No.	Supplier	Age (years)/gender	Cause of death	RIN <sup>1</sup>	
N1	Ambion	82/Female	Emphysema		9.6
N2	Ambion	20/Male	Head trauma		7.8
N3	Ambion	71/Male	Cerebral vascular accident		9.2
N4	Ambion	71/Male	Failure to thrive		9.1
BD	Clontech	35/Male	Sudden death		7.5
ST	Stratagene	72/Male	Chronic obstructive pulmonary disease		6.8
<i>Pancreatic adenocarcinoma tissues</i>					
Sample No.	Tumor pathology	Differentiation	Age (years)/gender	RIN	
				Tumor	Benign
OUP2	T3NxMx	Moderately	85/Male	8.2	7.0
OUP14	T3N0Mx invasive	Poor-moderate	71/Male	7.8	3.8
OUP16	T3N1bMx	Well	50/Male	5.6	5.6
OUP20	T3N1aMx	Poorly	70/Male	8.2	3.4
OUP27	T3N0Mx invasive	Moderate	86/Male	3.3	5.8
OUP29	T3N0Mx invasive	Poorly	63/Male	8.3	7.0
OUP28	T3N1bMx invasive	Poorly	48/Female	7.9	6.9
OUP31	T3N0Mx	Poorly	38/Male	7.7	7.0
OUP33	T3N1Mx	Poor-moderate	42/Female	5.1	8.3
OUP36	T3N1bMx	Moderate	56/Female	7.7	7.82 <sup>2</sup>
OUP37	T3N1bMx invasive	Mod-poor	79/Male	7.1	No tissue
OUP42	T3N0Mx invasive	Moderate	78/Female	6.6	7.6
OUP48	T3N1bMx invasive	Moderate	61/Male	8.1	4.3
OUP49	T3N1aMx invasive	Poor-moderate	62/Female	7.6	8.6
OUP91	T3N1bMx	Moderate	65/Male	5.9	6.1

## Normal pancreas tissues

Sample No.	Supplier	Age (years)/gender	Cause of death	RIN <sup>1</sup>
OUP97	T3N1bMx		Moderate	8.0
OUP101	T2N0Mx invasive		Moderate	56/Male
OUP105	T2N1aMx		Moderate	8.5
OUP122	T3N1aMx		Moderate	8.3
OUP123	T3N1bMx		Moderate-well	9.1
OUP135	T3N0Mx		Moderate	6.4
OUP139	T2N0Mx		Moderate	7.8
0206C077B(T)	T3N0Mx		Moderately	6.6
0206C138B(T)	T3N0MI		Intermediate to high grade	7.2
1050005A2(T)	T3N1Mx		Poorly	6.1
3030800A3(T)	T3N1Mx		Moderately	7.0
3030396A1(T)	Intraductal papillary mucinous tumor		—	7.5
3030401A1(T)	Intraductal papillary mucinous tumor		—	7.3
				8.9

<sup>1</sup> RNA integrity number from Agilent bioanalysis.<sup>2</sup> Benign tissue contained residual tumor and was not included in the study.

**TABLE II**

Top 20 aberrantly expressed miRNA precursors in pancreatic adenocarcinoma

Rank	Name	<i>p</i> -value ( <i>t</i> -test)	Fold change	Chromosome location
1	miR-221	5.66E-05	26.2	Xp11.3
2	miR-424	3.62E-08	56.3	Xq26.2
3	miR-301	1.11E-05	34.2	17q23.2
4	miR-100	4.40E-06	36.9	11q24.1
5	miR-376a	7.00E-04	7.79	14q32.31
6	miR-125b-1	1.00E-04	23.2	11q24.1
7	miR-021	2.00E-04	15.7	17q23.2
8	miR-345	1.44E-15	-14.5	14q32.2
9	miR-016-1	3.73E-04	14.3	13q14.2
10	miR-181a,c	8.31E-04	18.6	9q33.3, 19p13.13
11	miR-092-1	3.40E-03	19.6	13q31.3
12	miR-015b	4.00E-04	8.55	3q25.33
13	miR-142-P	3.63E-07	-15.4	17q23.2
14	miR-155	1.51E-03	14.0	21q21
15	let-7f-1	4.00E-04	10.9	9q22.32
16	miR-212	2.00E-04	22.2	17p13.3
17	miR-107	3.86E-05	8.20	10q23.31
18	miR-024-1,2	9.12E-08	8.17	9q22.32, 19p13
19	let-7d	7.06E-04	8.38	9q22.32
20	miR-139	6.79E-11	-7.91	11q13.4